The update on GeoVax's next-generation SARS-CoV-2 vaccine development indicates progress in preclinical studies and preparation for clinical trials. This positive news is likely to have a short-term positive impact on the company's stock price, as it demonstrates the company's commitment to advancing its vaccine candidate and potential future revenue generation.